Annotation Detail
Information
- Associated Genes
- KRAS
- Associated Variants
-
KRAS A146
KRAS A146 - Associated Disease
- colorectal cancer
- Source Database
- CIViC Evidence
- Description
- This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy. Patients harboring KRAS codon 146 mutant tumors (n=11) did not have a significantly lower response rate than did patients with KRAS wildtype tumors (2/11 [18.2%] vs 101/274 [36.9%]; p =0.34). Authors suggest that KRAS codon 146 mutations may not support resistance to cextuximab. Authors note that these patients were treated with cetuximab prior to widespread adoption of regular KRAS mutational status screening. Patients treated with cetuximab monotherapy were not included.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/3939
- Gene URL
- https://civic.genome.wustl.edu/links/genes/30
- Variant URL
- https://civic.genome.wustl.edu/links/variants/2979
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Colorectal Cancer
- Evidence Direction
- Does Not Support
- Drug
- Cetuximab,Chemotherapy
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 20619739
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Cetuximab | Resitance or Non-Reponse | false |
| Chemotherapy | Resitance or Non-Reponse | false |